- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07945236
FISH Detection of PML::RARA and BCR::ABL1
Validation of a Standardized FISH-Based Diagnostic Workflow for Detection of PML::RARA in Acute Promyelocytic Leukemia and BCR::ABL1 in Chronic Myeloid Leukemia
This cross-sectional study aims to establish and evaluate a standardized fluorescence in situ hybridization workflow for detection of PML::RARA in acute promyelocytic leukemia and BCR::ABL1 in chronic myeloid leukemia.
Study Overview
Status
Detailed Description
Acute promyelocytic leukemia is defined by the PML::RARA fusion, and chronic myeloid leukemia is defined by the BCR::ABL1 fusion. Fluorescence in situ hybridization (FISH) can detect these fusions rapidly on interphase cells.
This observational study will apply a standardized FISH workflow using dual-color dual-fusion probes for PML::RARA and BCR::ABL1. Laboratory-specific normal cut-off values will be established from control specimens, and the probes will be tested on confirmed positive specimens from newly diagnosed untreated patients.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Amira E Salah Eldin, Resident
- Phone Number: 01005305860
- Email: AmiraEhab@aun.edu.eg
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia, and individuals without hematologic malignancy who have a normal karyotype, at Assiut University Hospitals.
Description
Inclusion Criteria:
- - Newly diagnosed untreated acute promyelocytic leukemia with PML::RARA
- Newly diagnosed untreated chronic myeloid leukemia with BCR::ABL1
- Adequate bone marrow or peripheral blood sample
- Control individuals without hematologic malignancy and with normal karyotype
- Written informed consent
Exclusion Criteria:
- Prior chemotherapy, all-trans retinoic acid, arsenic trioxide, or tyrosine kinase inhibitors
- Relapsed or secondary leukemia
- Hematologic malignancy in control group
- Refusal of informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
|---|
|
Leukemia Patients
Newly diagnosed untreated patients with acute promyelocytic leukemia or chronic myeloid leukemia. |
|
Controls
Individuals without hematologic malignancy who have a normal karyotype. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of nuclei showing positive FISH signal pattern
Time Frame: Baseline
|
Number of interphase nuclei showing the expected positive signal pattern for PML::RARA or BCR::ABL1 by fluorescence in situ hybridization (out of 200 nuclei scored per case). |
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Normal cut-off values for FISH signals
Time Frame: Baseline
|
Laboratory-specific normal cut-off values (percentage) for each fluorescence in situ hybridization signal pattern calculated from control specimens using the inverse beta function. |
Baseline
|
|
Number of cases with typical signal pattern
Time Frame: Baseline
|
Number of confirmed positive cases showing the typical dual-fusion signal pattern by fluorescence in situ hybridization. |
Baseline
|
|
Inter-observer concordance rate
Time Frame: Baseline
|
Percentage of agreement between two independent scorers for fluorescence in situ hybridization signal patterns. |
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Zeinab A Abdel-Hafez, prof, Clinical pathology Department, Assiut University Hospitals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Chronic Disease
- Disease Attributes
- Neoplasms by Histologic Type
- Hematologic Diseases
- Leukemia, Myeloid
- Bone Marrow Diseases
- Leukemia
- Myeloproliferative Disorders
- Leukemia, Myeloid, Acute
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Promyelocytic, Acute
Other Study ID Numbers
- FISH-APL-CML-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.